These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.

Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.

2 Stocks to Add to Your Watchlist

The Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate. The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction.

The final step today is to look at a stock that meets our ESP qualifications. Novartis (NVS) earns a Zacks Rank #3 29 days from its next quarterly earnings release on October 25, 2022, and its Most Accurate Estimate comes in at $1.59 a share.

NVS has an Earnings ESP figure of 1.27%, which, as explained above, is calculated by taking the percentage difference between the $1.59 Most Accurate Estimate and the Zacks Consensus Estimate of $1.57.

NVS is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Doximity (DOCS) as well.

Doximity is a Zacks Rank #3 (Hold) stock, and is getting ready to report earnings on November 8, 2022. DOCS' Most Accurate Estimate sits at $0.17 a share 43 days from its next earnings release.

Doximity's Earnings ESP figure currently stands at 4.76% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.16.

NVS and DOCS' positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're Reported

Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
Doximity, Inc. (DOCS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research